Monia Brett P
Chief Executive Officer at IONS
- Sold, on record
- $65.4M
- Dollars the filings state
- Form 4 sales
- 64
- Latest Jun 26, 2026
- Form 144 notices
- 11
- Proposed sales
- Companies
- 1
- Filed as an executive or holder
Companies
- IONSIONIS PHARMACEUTICALS INCChief Executive Officer
Sales by reason
Form 4 sales per month, last 12 months.
Timeline
- 1 Form 4 sale IONSUnusualSep 3 2025
Sold 203,814 shares at $60.32 ($12.3M)
Monia Brett P, Chief Executive Officer
No 10b5-1 planSold 53.1% of holdings ($23.2M position)180,009 shares left20.5x usual sizeFiling
- 2 Form 4 sale IONSRoutineOct 6 +33 days
Sold 437 shares at $69.26 ($30k)
Monia Brett P, Chief Executive Officer
10b5-1 planSold 0.2% of holdings ($12.5M position)179,572 shares left0x usual sizeFiling
- 3 Form 4 sale IONSUnusualJan 16 +102 days
Sold 44,034 shares at $74.82 ($3.3M)
Monia Brett P, Chief Executive Officer
No 10b5-1 planSold 16.4% of holdings ($20.1M position)224,683 shares left6.6x usual sizeFiling
- 4 Form 4 sale IONSUnusualJan 30 +14 days
Sold 62,970 shares at $82.72 ($5.2M)
Monia Brett P, Chief Executive Officer
No 10b5-1 planSold 18.2% of holdings ($28.7M position)283,927 shares left6.3x usual sizeFiling
- 5 Form 4 sale IONSRoutineFeb 6 +7 days
Sold 29,430 shares at $85.79 ($2.5M)
Monia Brett P, Chief Executive Officer
10b5-1 planSold 10.4% of holdings ($24.4M position)254,497 shares left3x usual sizeFiling
- 6 Form 4 sale IONSUnusualMar 10 +32 days
Sold 160,773 shares at $75.35 ($12.1M)
Monia Brett P, Chief Executive Officer
10b5-1 planSold 39.9% of holdings ($30.4M position)242,662 shares left7.5x usual sizeFiling
- 7 Form 4 sale IONSRoutineMay 14 +65 days
Sold 4,536 shares at $78.49 ($356k)
Monia Brett P, Chief Executive Officer
10b5-1 planSold 1.8% of holdings ($19.4M position)242,662 shares left0.2x usual sizeFiling
- 8 Form 4 sale IONSUnusualJun 26 +43 days
Sold 85,637 shares at $79.70 ($6.8M)
Monia Brett P, Chief Executive Officer
10b5-1 planSold 25.9% of holdings ($26.4M position)245,571 shares left4x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (75)
| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IONS | Chief Executive Officer | Form 4 sale | 85,637 | $6.8M | 25.9% | Unusual | SEC |
| May 14, 2026 | IONS | Chief Executive Officer | Form 4 sale | 4,536 | $356k | 1.8% | Routine | SEC |
| Mar 10, 2026 | IONS | Chief Executive Officer | Form 4 sale | 160,773 | $12.1M | 39.9% | Unusual | SEC |
| Feb 6, 2026 | IONS | Chief Executive Officer | Form 4 sale | 29,430 | $2.5M | 10.4% | Routine | SEC |
| Jan 30, 2026 | IONS | Chief Executive Officer | Form 4 sale | 62,970 | $5.2M | 18.2% | Unusual | SEC |
| Jan 16, 2026 | IONS | Chief Executive Officer | Form 4 sale | 44,034 | $3.3M | 16.4% | Unusual | SEC |
| Oct 6, 2025 | IONS | Chief Executive Officer | Form 4 sale | 437 | $30k | 0.2% | Routine | SEC |
| Sep 3, 2025 | IONS | Chief Executive Officer | Form 4 sale | 203,814 | $12.3M | 53.1% | Unusual | SEC |
| Jul 30, 2025 | IONS | Chief Executive Officer | Form 4 sale | 2,432 | $109k | 1.3% | Routine | SEC |
| Jul 11, 2025 | IONS | Chief Executive Officer | Form 4 sale | 1,160 | $48k | 0.6% | Routine | SEC |
| Mar 11, 2025 | IONS | Chief Executive Officer | Form 4 sale | 140 | $5k | 0.1% | Routine | SEC |
| Feb 4, 2025 | IONS | Chief Executive Officer | Form 4 sale | 38,843 | $1.2M | 17.7% | Routine | SEC |
| Jan 31, 2025 | IONS | Chief Executive Officer | Form 4 sale | 13,242 | $430k | 5.7% | No plan | SEC |
| Jan 16, 2025 | IONS | Chief Executive Officer | Form 4 sale | 33,445 | $1.1M | 13.9% | No plan | SEC |
| Nov 12, 2024 | IONS | Chief Executive Officer | Form 4 sale | 6,630 | $252k | 3.8% | Routine | SEC |
| Feb 16, 2024 | IONS | Officer, Director | Form 144 notice | 387 | $17k | Notice | SEC | |
| Feb 16, 2024 | IONS | Chief Executive Officer | Form 4 sale | 387 | $17k | 0.2% | Routine | SEC |
| Feb 2, 2024 | IONS | Officer, Director | Form 144 notice | 23,501 | $1.2M | Notice | SEC | |
| Feb 2, 2024 | IONS | Chief Executive Officer | Form 4 sale | 23,501 | $1.2M | 11.9% | No plan | SEC |
| Jan 26, 2024 | IONS | Officer, Director | Form 144 notice | 2,285 | $118k | Notice | SEC | |
| Jan 25, 2024 | IONS | Chief Executive Officer | Form 4 sale | 2,285 | $118k | 1.5% | Routine | SEC |
| Jan 17, 2024 | IONS | Chief Executive Officer | Form 4 sale | 32,059 | $1.6M | 17.2% | No plan | SEC |
| Jan 17, 2024 | IONS | Officer, Director | Form 144 notice | 32,059 | $1.6M | Notice | SEC | |
| Dec 22, 2023 | IONS | Officer, Director | Form 144 notice | 24,000 | $1.2M | Notice | SEC | |
| Dec 21, 2023 | IONS | Chief Executive Officer | Form 4 sale | 24,000 | $1.2M | 16.9% | Routine | SEC |
| Dec 15, 2023 | IONS | Officer, Director | Form 144 notice | 10,613 | $526k | Notice | SEC | |
| Dec 14, 2023 | IONS | Chief Executive Officer | Form 4 sale | 24,000 | $1.2M | 16.9% | Routine | SEC |
| Oct 12, 2023 | IONS | Chief Executive Officer | Form 4 sale | 3,770 | $173k | 3.1% | Routine | SEC |
| Oct 12, 2023 | IONS | Officer, Director | Form 144 notice | 3,770 | $173k | Notice | SEC | |
| Jul 7, 2023 | IONS | Chief Executive Officer | Form 4 sale | 18,650 | $788k | 13.3% | Routine | SEC |
| Jul 7, 2023 | IONS | Officer, Director | Form 144 notice | 18,650 | $788k | Notice | SEC | |
| May 22, 2023 | IONS | Chief Executive Officer | Form 4 sale | 4,931 | $198k | 3.4% | Routine | SEC |
| May 22, 2023 | IONS | Officer, Director | Form 144 notice | 4,931 | $198k | Notice | SEC | |
| Feb 6, 2023 | IONS | Chief Executive Officer | Form 4 sale | 24,651 | $1M | 14.5% | Unusual | SEC |
| Feb 6, 2023 | IONS | Officer, Director | Form 144 notice | 24,651 | $1M | Notice | SEC | |
| Jan 18, 2023 | IONS | Chief Executive Officer | Form 4 sale | 25,066 | $990k | 17.2% | Plan not stated | SEC |
| Jan 18, 2023 | IONS | Officer, Director | Form 144 notice | 24,000 | $984k | Notice | SEC | |
| Apr 1, 2022 | IONS | Chief Executive Officer | Form 4 sale | 355 | $13k | 0.4% | Plan not stated | SEC |
| Mar 1, 2021 | IONS | Chief Executive Officer | Form 4 sale | 236 | $13k | 0.5% | Plan not stated | SEC |
| Dec 4, 2020 | IONS | Chief Executive Officer | Form 4 sale | 23,840 | $1.2M | 45.2% | Unusual | SEC |
| Dec 2, 2020 | IONS | Chief Executive Officer | Form 4 sale | 21,160 | $1.1M | 42.3% | Unusual | SEC |
| Sep 1, 2020 | IONS | Chief Executive Officer | Form 4 sale | 314 | $17k | 1.1% | Plan not stated | SEC |
| Jan 2, 2020 | IONS | Chief Executive Officer | Form 4 sale | 173 | $10k | 1.1% | Plan not stated | SEC |
| Nov 20, 2019 | IONS | COO & SVP, Translational Med | Form 4 sale | 5,776 | $347k | 26.0% | Unusual | SEC |
| Jul 2, 2019 | IONS | Chief Operating Officer | Form 4 sale | 210 | $14k | 0.9% | Plan not stated | SEC |
| Jan 2, 2019 | IONS | Chief Operating Officer | Form 4 sale | 214 | $11k | 1.3% | Plan not stated | SEC |
| Nov 23, 2018 | IONS | Chief Operating Officer | Form 4 sale | 34,000 | $1.9M | 68.2% | Unusual | SEC |
| Aug 27, 2018 | IONS | Chief Operating Officer | Form 4 sale | 16,493 | $891k | 51.0% | Unusual | SEC |
| Jul 24, 2018 | IONS | Chief Operating Officer | Form 4 sale | 156 | $7k | 1.0% | Plan not stated | SEC |
| Jan 16, 2018 | IONS | COO | Form 4 sale | 2,821 | $146k | 15.2% | Unusual | SEC |
| Jan 2, 2018 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 163 | $8k | 1.4% | Plan not stated | SEC |
| Jul 3, 2017 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 309 | $16k | 2.6% | Plan not stated | SEC |
| Jan 17, 2017 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 2,502 | $116k | 17.5% | Unusual | SEC |
| Jan 3, 2017 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 309 | $15k | 3.8% | Plan not stated | SEC |
| Dec 20, 2016 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 130 | $7k | 1.6% | Plan not stated | SEC |
| Jan 19, 2016 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 2,208 | $92k | 22.3% | Unusual | SEC |
| Jan 4, 2016 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 127 | $8k | 2.8% | Plan not stated | SEC |
| Jul 2, 2015 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 198 | $11k | 4.3% | Plan not stated | SEC |
| Jun 8, 2015 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 7,600 | $503k | 63.2% | Unusual | SEC |
| Jan 16, 2015 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 1,534 | $104k | 25.7% | Unusual | SEC |
| Jan 2, 2015 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 76 | $5k | 3.8% | Plan not stated | SEC |
| Aug 26, 2014 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 27,344 | $1M | 93.8% | Unusual | SEC |
| Jul 31, 2014 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 79 | $2k | 4.2% | Plan not stated | SEC |
| Jan 16, 2014 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 821 | $39k | 31.1% | Unusual | SEC |
| Jan 2, 2014 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 362 | $14k | 42.7% | Unusual | SEC |
| Sep 20, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 68,281 | $2.3M | 98.9% | Unusual | SEC |
| Aug 26, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 2,909 | $74k | 79.1% | Unusual | SEC |
| Jul 2, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 215 | $6k | 3.5% | Plan not stated | SEC |
| Jun 11, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 9,375 | $223k | 62.2% | Unusual | SEC |
| Apr 22, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 19,500 | $415k | 77.4% | Unusual | SEC |
| Mar 5, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 18,240 | $308k | 76.2% | Unusual | SEC |
| Jan 16, 2013 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 330 | $5k | 5.5% | Plan not stated | SEC |
| Jan 3, 2013 | IONS | VP, Antisense Drug Discovery | Form 4 sale | 311 | $3k | 5.6% | Plan not stated | SEC |
| Sep 6, 2012 | IONS | VP, Antisense Drug Discovery | Form 4 sale | 12,031 | $183k | 69.1% | Unusual | SEC |
| Jul 3, 2012 | IONS | SVP, Antisense Drug Discovery | Form 4 sale | 587 | $8k | 9.8% | Plan not stated | SEC |